SavedAdd your journal

Journals / Journal of Health Sciences and Medicine / 2021 / Cilt: 4 - Sayı: 5

Evaluation of serum perlecan levels in pregnancy with mild and severe preeclampsia

Ugurkan ERKAYIRAN
Abdullah TOK
Selim KARAKÜÇÜK
Muhammed SEYİTHANOĞLU
Tufan ARSLANCA
Pages
538–542
Publication Date
2021-09-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Perlecan level in group 1 was determined at higher levels than other groups, and this level difference was statistically significant compared to the other two groups (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To determine the levels of perlecan, which contributes to autophagy inhibition and angiogenesis, in severe and mild preeclamptic women.
📊
Key Findings & Data:Material and Method: A total of 89 patients including severe preeclampsia, group 1 (n: 30), mild preeeclampsia, group 2 (n: 30) and control group, group 3 (n: 29) were included in the study.
💡
Conclusion & Impact:Perlecan level in group 1 was determined at higher levels than other groups, and this level difference was statistically significant compared to the other two groups (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Perlecan · preeclampsia · autophagy

Abstract

Aim: To determine the levels of perlecan, which contributes to autophagy inhibition and angiogenesis, in severe and mild preeclamptic women. Material and Method: A total of 89 patients including severe preeclampsia, group 1 (n: 30), mild preeeclampsia, group 2 (n: 30) and control group, group 3 (n: 29) were included in the study. Results: All three groups were evaluated in terms of perlecan levels. Perlecan level in group 1 was determined at higher levels than other groups, and this level difference was statistically significant compared to the other two groups (p

🔖

Cite This Article

ERKAYIRAN, U., TOK, A., KARAKÜÇÜK, S., SEYİTHANOĞLU, M., ARSLANCA, T. (2021). Evaluation of serum perlecan levels in pregnancy with mild and severe preeclampsia. Journal of Health Sciences and Medicine, Cilt: 4 - Sayı: 5, 538–542. https://ajindex.com/articles/776787

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. El-Sayed AAF. Preeclampsia: A review of the pathogenesis and possible management strategies based on its pathophysiological derangements. Taiwanese J Obstet Gynecol 2017; 56: 593-8.
  2. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013; 170: 1-7.
  3. Oh SY, Hwang JR, Choi M, et al. Autophagy regulates trophoblast invasion by targeting NF-κB activity. Scientific Reports Sci Rep.2020; 10: 14033. Nakashima A, Aoki A, Kusabiraki T, Cheng SB, Sharma S, Saito S. Autophagy regulation in preeclampsia: Pros and cons. Journal of Reproductive Immunology 2017; 123: 17-23.
  4. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the “chickenand-egg” question, Endocrinology 2004; 145: 4835-7.
  5. Smets EML, Visser, Go ATJI, Vugt JMGV, Oudejans CBM. Novel biomarkers in preeclampsia. Clin Chim Acta 2006; 364: 22-32.
  6. Ramos JGL, Sass N, Costa SHM. Preeclampsia. Rev Bras Ginecol Obstet 2017; 39: 496-512.
  7. Nakashima A, Yamanaka-Tatematsu M, Fujita N, et al. Impaired autophagy by soluble endoglin, under physiological hypoxia in early pregnant period, is involved in poor placentation in preeclampsia. Autophagy 2013; 9: 303-16.
  8. Kalkat M, Garcia J, Ebrahimi J, et al. Placental autophagy regulation by the BOK-MCL1 rheostat. Autophagy 2013; 9: 2140-53.
  9. Jiang X, Couchman JR. Perlecan and tumor angiogenesis. J Histochem Cytochem 2003; 51: 1393-410.
  10. Ning L, Xu Z, Furuya N, Nonaka R, Yamada Y, Arikawa-Hirasawa E. Perlecan inhibits autophagy to maintain muscle homeostasis in mouse soleus muscle, Matrix Biol 2015; 48: 26-35.
  11. Gubbiotti MA, Neill T, Iozzo RV. A current view of perlecan in physiology and pathology: A mosaic of functions. Matrix Biol 2017; 57-58: 285-98.
  12. Vuadens F, Benay C, Crettaz D, et al. Identification of biologic markers of the prematüre rupture of fetal membranes: Proteomic approach. Proteomics 2003; 3: 1521-5.
  13. Akbas M, Koyuncu FM, Ulkumen BA, Taneli F, Ozdemir H. Maternal serum perlecan levels in women with preeclampsia. Hypertens Pregnancy 2020; 39: 70-6.
  14. Szenasi NL, Toth E, Balogh A, et al. Proteomic identification of membrane-associated placental protein 4 (MP4) as perlecan and characterization of its placental expression in normal and pathologic pregnancies. PeerJ 2019; 7: e6982. Yang WC, Su TH, Yang YC, Chang SC, Chen CY, Chen CP. Altered perlecan expression in placental development and gestational diabetes mellitus. Placenta 2005; 26: 780–8.
  15. Chui A, Murthi